QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.007369v1 34/3/449    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uchaipichat, V. Articles by Miners, J. O. Search for Related Content PubMed PubMed Citation Articles by Uchaipichat, V. Articles by Miners, J. O.

SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) "PROBES" FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES

Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia

Relatively few selective substrate and inhibitor probes have been identified for human UDP-glucuronosyltransferases (UGTs). This work investigated the selectivity of trifluoperazine (TFP), as a substrate, and amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone, as inhibitors, for human UGTs. Selectivity was assessed using UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B7, and 2B15 expressed in HEK293 cells. TFP was confirmed as a highly selective substrate for UGT1A4. However, TFP bound extensively to both HEK293 lysate and human liver microsomes in a concentration-dependent manner (fu_inc 0.20–0.59). When corrected for nonspecific binding, K_m values for TFP glucuronidation were similar for both UGT1A4 (4.1 µM) and human liver microsomes (6.1 ± 1.2 µM) as the enzyme sources. Of the compounds screened as inhibitors, hecogenin, alone, was selective; significant inhibition was observed only for UGT1A4 (IC₅₀ 1.5 µM). Using phenylbutazone and quinine as "models," inhibition kinetics were variously described by competitive and noncompetitive mechanisms. Inhibition of UGT2B7 by quinidine was also investigated further, because the effects of this compound on morphine pharmacokinetics (a known UGT2B7 substrate) have been ascribed to inhibition of P-glycoprotein. Quinidine inhibited human liver microsomal and recombinant UGT2B7, with respective K_i values of 335 ± 128 µM and 186 µM. In conclusion, TFP and hecogenin represent selective substrate and inhibitor probes for UGT1A4, although the extensive nonselective binding of the former should be taken into account in kinetic studies. Amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone are nonselective UGT inhibitors.

This article has been cited by other articles:

				M.-O. Benoit-Biancamano, J. Connelly, L. Villeneuve, P. Caron, and C. Guillemette Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants Drug Metab. Dispos., February 1, 2009; 37(2): 322 - 329. [Abstract] [Full Text] [PDF]

				H. Shiratani, M. Katoh, M. Nakajima, and T. Yokoi Species Differences in UDP-Glucuronosyltransferase Activities in Mice and Rats Drug Metab. Dispos., September 1, 2008; 36(9): 1745 - 1752. [Abstract] [Full Text] [PDF]

				H.-X. Liu, Y. Liu, J.-W. Zhang, W. Li, H.-T. Liu, and L. Yang UDP-Glucuronosyltransferase 1A6 Is the Major Isozyme Responsible for Protocatechuic Aldehyde Glucuronidation in Human Liver Microsomes Drug Metab. Dispos., August 1, 2008; 36(8): 1562 - 1569. [Abstract] [Full Text] [PDF]

				A. Rowland, K. M. Knights, P. I. Mackenzie, and J. O. Miners The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities Drug Metab. Dispos., June 1, 2008; 36(6): 1056 - 1062. [Abstract] [Full Text] [PDF]

				B. Zhu, D. Bush, G. A. Doss, S. Vincent, R. B. Franklin, and S. Xu Characterization of 1'-Hydroxymidazolam Glucuronidation in Human Liver Microsomes Drug Metab. Dispos., February 1, 2008; 36(2): 331 - 338. [Abstract] [Full Text] [PDF]

				R. Fujiwara, M. Nakajima, H. Yamanaka, M. Katoh, and T. Yokoi Interactions between Human UGT1A1, UGT1A4, and UGT1A6 Affect Their Enzymatic Activities Drug Metab. Dispos., October 1, 2007; 35(10): 1781 - 1787. [Abstract] [Full Text] [PDF]

				T. Kubota, B. C. Lewis, D. J. Elliot, P. I. Mackenzie, and J. O. Miners Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4 Mol. Pharmacol., October 1, 2007; 72(4): 1054 - 1062. [Abstract] [Full Text] [PDF]

				S. J. Miyagi and A. C. Collier Pediatric Development of Glucuronidation: The Ontogeny of Hepatic UGT1A4 Drug Metab. Dispos., September 1, 2007; 35(9): 1587 - 1592. [Abstract] [Full Text] [PDF]

				R. Fujiwara, M. Nakajima, H. Yamanaka, A. Nakamura, M. Katoh, S.-i. Ikushiro, T. Sakaki, and T. Yokoi Effects of Coexpression of UGT1A9 on Enzymatic Activities of Human UGT1A Isoforms Drug Metab. Dispos., May 1, 2007; 35(5): 747 - 757. [Abstract] [Full Text] [PDF]

				O. Kerdpin, D. J. Elliot, P. I. Mackenzie, and J. O. Miners Sulfinpyrazone C-Glucuronidation Is Catalyzed Selectively by Human UDP-Glucuronosyltransferase 1A9 Drug Metab. Dispos., December 1, 2006; 34(12): 1950 - 1953. [Abstract] [Full Text] [PDF]

				A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062. [Abstract] [Full Text] [PDF]